Integra: One Flood, One 9.5% Coupon, and the Words That Disappeared

A $30 million guidance cut is the headline. The more revealing story is which themes management quietly stopped talking about — and which market-wide wave they just refinanced into.

IART · Earnings Call · 2026-10-21

The tape voted before the call did

The stock has already delivered the verdict. IART fell 32% across the ninety sessions to October 21 in one unbroken down segment, sits 40% below its July 16 close of $19.85, and is 84.5% under the 2021 peak of $76.63. Market capitalization is now roughly $920 million, and investors are paying about 0.8x revenue. The October 2 preliminary release did the damage; the October 21 call mostly explained it. The quarter itself was not a disaster: revenue of $411.2 million, up 2.3% reported and 2.5% organically, adjusted EPS of $0.59 against $0.54, and $96 million of operating cash flow. The problem is the forward vector. Fourth-quarter revenue is guided to $413–433 million, an organic decline of 5.1% to 0.4%, and the full-year midpoint came down by roughly $30 million. After three years of supply chaos, revenue has effectively gone sideways since 2023.

Cincinnati is a company wound, not a market wave

The defining theme of this quarter is entirely self-inflicted by weather. Cincinnati disruption tops the company's keyword board, flanked by MAYFIELD, lost revenues, business interruption and insurance reimbursements. Check that against the market: the global keyword boards over the last twelve quarters are crowded with weather events — Hurricane Helene, Hurricane Milton, Winter Storm Fern — but none of them is a company's own plant. This is not Integra riding a wave; it is Integra standing in one. Stuart Essig was blunt about the quarter's shape: “the Cincinnati disruption proved more significant than initially expected, and growth in Tissue Reconstruction did not materialize as anticipated” — Stuart Essig, Chairman and Chief Executive Officer · 2026-10-21. The flood cost roughly $7 million of third-quarter revenue, with another $15–20 million expected in the fourth quarter, all of the first quarter of 2027 affected, and shipments resuming — with no backorder clearance assumed — in the second quarter. “We'll certainly lose some business to some of the smaller competition” — Stuart Essig, Chairman and Chief Executive Officer · 2026-10-21, Essig conceded, while leaning on a large loaner pool and the fact that surgeons trained on MAYFIELD for fifty years will wait. One accounting detail matters for the reported numbers: insurance recoveries for business interruption stay inside adjusted results, while remediation costs and inventory write-offs come out. That is a defensible choice, but it means adjusted EPS is partly an insurance receivable whose timing management explicitly said may lag the loss.

Tissue Reconstruction went from headline to footnote

Last quarter Tissue Reconstruction was the company's single highest-momentum keyword. This quarter it sits near the bottom of the top-30, and the reason is instructive: the story changed from recovery to competition. pressure in UBM now enters the board directly, because MicroMatrix has been losing ground to newer powder-form entrants, and Integra Skin has been losing burn accounts where “there are competitors who've come in and for the most part, competed on price” — Stuart Essig, Chairman and Chief Executive Officer · 2026-10-21. The segment that was supposed to be the recovery engine is now the reason the guide came down a second time. Lea Knight put a floor under expectations for next year:

We would anticipate that the base, what I'll call base Tissue Reconstruction, will continue to be flat in 2027 versus 2026.
Lea Knight, Chief Financial Officer · 2026-10-21

That is a meaningful admission. It means SurgiMend's return — the December limited launch, the 2027 PMA label, the planned expansion from roughly 30 to 50 breast-reconstruction reps — has to carry the entire growth argument for the segment. Meanwhile the private-label business got a rebrand to Corporate Partnerships, a graceful way to describe a line that was, in the company's own words, approximately flat.

The disappearing acts

What management stopped saying is as loud as what it started. As recently as July, MediHoney was a promised 2027 return-to-market with demand in hand: “we continue to advance the work to bring MediHoney back to market in 2027. We are including nothing in our 2026 guidance for MediHoney” — Stuart Essig, Chairman, President and Chief Executive Officer · 2026-07-29. On this call it is not mentioned once — not in prepared remarks, not in eight analyst questions. CUSA, once a centerpiece (new cardiovascular and OBGYN clearances, Japan, Korea, India, liver surgery), is now a two-sentence aside and "about 6% of Integra's revenue." Then there is commercial execution, which has been a top-ten keyword for this company across multiple quarters. In May, Essig framed his return as “going on the offense commercially” — Stuart Essig, Chairman, President and Chief Executive Officer · 2026-05-05. Seven months and one chief commercial officer later, the fix is still being prescribed in the same words. A repeated diagnosis is a different thing from a fresh one, and the market appears to have noticed.

Where the company meets the market: the 9.5% coupon

The genuinely new theme is refinancing. On October 19 Integra closed $2.1 billion: a $1.65 billion senior secured credit facility plus $450 million of 9.5% secured notes due 2033. It extends maturities and adds covenant room, and management sells it as financial flexibility. But it costs: $8 million of extra interest in Q4 alone, and a further $24 million in 2027. Leverage is 3.8x against a 2.5–3.5x target, and management expects to finish 2026 "just above" that range. The important context is that this is no longer a purely company-specific story. The market's own keyword board for the latest quarter is dominated by the hiking cycle, Fed rate hikes and the impact of high rates — and the roster of companies reporting this week is littered with banks citing "rate hike" language. Integra took a fifteen-quarter-old supply-chain problem and refinanced it into a market-wide rate regime. That is why interest coverage of roughly 0.8x is the number to watch next year, not the revenue line. Management's offsets are real but soft: $10–15 million of annualized transformation savings, lower remediation and consulting spend, and improving productivity. In July the same CFO was more confident that costs would fully absorb the interest bill: “we do expect to be able to offset the incremental interest expense headwind... through additional cost savings” — Lea Daniels Knight, Chief Financial Officer · 2026-07-29. On this call the promise shifted to "we do expect growth in EPS" — true, but a lower bar.

The bottom line

Nine months ago this was a company fixing its quality system. Today it is a company with a flooded plant, a competitive problem in the one segment meant to lead the recovery, a 9.5% cost of debt, and a gross margin that has shed nine points in three years. The record $96 million of cash flow is genuine but flattered by the roll-off of Braintree and EU MDR spending — the free-cash-flow margin underneath is still thin. The stock is priced for a turnaround and a workout at the same time. Whether it gets one depends less on demand, which looks fine, and more on whether "stronger commercial execution" finally becomes a description rather than a promise.